New Drug S9788 Helps Overcome Cancer Drug Resistance
Author Information
Author(s): A.-M. Julia, H. Roche, M. Berlion, C. Lucas, G. Milano, J. Robert, J.-P. Bizzari, P. Canal
Primary Institution: Centre Claudius Regaud
Hypothesis
The study investigates how the timing and duration of exposure to S9788 affects its ability to reverse doxorubicin resistance in cancer cells.
Conclusion
S9788 is more effective than verapamil in reversing drug resistance in cancer cells when administered in a specific schedule.
Supporting Evidence
- S9788 was found to be more potent than verapamil in reversing drug resistance.
- The best results were achieved when S9788 was administered before, during, and after doxorubicin treatment.
- Cellular accumulation of doxorubicin increased significantly in the presence of S9788.
Takeaway
Researchers found that a new drug called S9788 can help cancer cells respond better to treatment by changing how and when it's given.
Methodology
The study used clonogenic assays to measure cell survival and drug accumulation in MCF7/DOX cell lines under various treatment schedules.
Limitations
The study was conducted in vitro, and the results may not fully translate to clinical settings.
Want to read the original?
Access the complete publication on the publisher's website